Rockefeller University Press

TABLE I.

Comparison of blocker impact on R_IV for all HEK 293 constructs

Drug order	Basal^a	Forskolin	GlyH-101	Forskolin+GlyH-101	Forskolin+Glibenclamide	GlyH-101+Forskolin	Glibenclamide+Forskolin
Construct
SLC26A9	0.98 ± 0.03	0.96 ± 0.04	0.85 ± 0.02	0.83 ± 0.02	0.95 ± 0.02	nt^b	nt
wtCFTR	1.30 ± 0.05	0.98 ± 0.01	0.96 ± 0.04^c	0.42 ± 0.03	1.84 ± 0.02	0.35 ± 0.01	1.82 ± 0.03
SLC26A9 + wtCFTR	1.04 ± 0.04	0.99 ± 0.01	0.84 ± 0.04	0.62 ± 0.05	1.41 ± 0.10	0.50 ± 0.07	1.40 ± 0.09

Drug order	Basal^a	Forskolin	GlyH-101	Forskolin+GlyH-101	Forskolin+Glibenclamide	GlyH-101+Forskolin	Glibenclamide+Forskolin
Construct
SLC26A9	0.98 ± 0.03	0.96 ± 0.04	0.85 ± 0.02	0.83 ± 0.02	0.95 ± 0.02	nt^b	nt
wtCFTR	1.30 ± 0.05	0.98 ± 0.01	0.96 ± 0.04^c	0.42 ± 0.03	1.84 ± 0.02	0.35 ± 0.01	1.82 ± 0.03
SLC26A9 + wtCFTR	1.04 ± 0.04	0.99 ± 0.01	0.84 ± 0.04	0.62 ± 0.05	1.41 ± 0.10	0.50 ± 0.07	1.40 ± 0.09

Order of agonist or blocker represents experimental additions. Each measurement represents an n ≥ 3.

Basal values given are for cells subsequently exposed to forskolin.

nt, not tested.

CFTR was inactive with Im = −0.09 ± 0.27 pA/pF.